Diabetes

At the 79th Annual Scientific Sessions of the American Diabetes Association in San Francisco, pharma giant Roche and India-based digital therapeutics company Wellthy Therapeutics presented real world data of improved diabetes care outcomes in a South Asian population when patients followed prescribed plan of medication and lifestyle modification in conjunction with a combination therapy of self-monitoring blood glucose device and a clinically validated digital therapeutic (DTx).

Oxfordshire-based Satellite Applications Catapult has already been working with the NHS Arden & GEM CSU for the past year and a half.

An interview with Siddharth Sharma, patient advocate speaking at the HIMSS & Health 2.0 European conference in Helsinki this June.

Biolinq's new funding was led by JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners. 

The Eversense Bridge program is geared toward patients with high-deductible insurance plans or plans that don't cover the full cost of Eversense CGM, and allows them to purchase the system for $99. 

The company will augment its BYOD strategy with optional included sensors.

The tool considers vascular changes and individual risk data to make its predictions.

Reactions to the news are mixed, with some experts saying the test is unlikely to make much of a difference.

Users of the Eversense CGM will be able to transfer their data to Glooko's online diabetes management platform. 

Dexcom announced a slew of announcements this morning including an integration with Google Fit, a feature that lets users share their readings with 10 people and a technical inquiries feature.